Skip to main content

Advertisement

Table 2 Pazopanib efficacy data from comparative studies

From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

VARIABLE STUDY DRUGS OUTCOME STATISTICS
Progression-free survival VEG105192 [14] Pazopanib vs placebo 11.1 vs 2.8 months HRa=0.40; 95% CIb: 0.27–0.60
  COMPARZ [24] (non-inferiority) Pazopanib vs sunitinib 8.4 vs 9.5 months HR = 1.05; 95% CI: 0.90–1.22
  International mRCC Database Consortium (IMDC) [26] Pazopanib vs sunitinib 8.3 vs 8.3 months (HR = 1.08; 95% CI: 0.98–1.19)
Response rate VEG105192 Pazopanib vs placebo 30% vs 3% Pazopanib: 95% CI: 25.1–35.6Placebo: 95% CI: 0.5–6.4
  COMPARZ (non-inferiority) Pazopanib vs placebo 31% vs 25% p = 0.003
Overall survival VEG105192 [14] Pazopanib vs placebo 22.9 vs 20.5 months HR = 0.91; 95% CI: 0.71–1.16
  COMPARZ (non-inferiority) Pazopanib vs sunitinib 28.4 vs 29.3 months HR = 0.91; 95% CI: 0.76–1.08
  1. aHR: hazard ratio bCI: confidence interval;